Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

ONCOLife Issues

ONCOLife Articles


Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved a 51 percent overall response rate in RAS/BRAF wild-type metastatic colorectal cancer, rising to 73 percent in first-line patients....
















About Image

About ONCOLife

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is dedicated to covering key developments in the field of oncology. We delve into the stories behind significant clinical research and drug developments, highlight the latest news, and offer exclusive interviews.